European Medicines Agency starts consultation on inventory of needs for children's medicines
The European Medicines Agency has begun its first public consultation on its inventory of paediatric medicines.
The European Medicines Agency has begun its first public consultation on its inventory of paediatric medicines.
This inventory, which is being developed by the Agency's Paediatric Committee (PDCO), sets out areas where further research and development into medicines for children are needed. It aims to enable:
companies to identify opportunities for business development;
the PDCO to judge the need for medicines and studies when assessing draft paediatric investigation plans, waivers and deferrals;
healthcare professionals and patients to have an information source available to support their decisions as to which medicines.
The inventory is based on a report on the survey of all paediatric uses of medicinal products in Europe completed by the PDCO in December 2010.
The first list, released today, includes all cardiovascular medicines for use in children. The Agency will be releasing similar lists for other therapeutic areas for public consultation during 2012 and 2013.
The list is open for comments until 30 October 2012. Comments should be sent to [email protected] with 'comments on the list of paediatric needs' in the subject line. After the consultation period, the PDCO will review all comments and amend the document as necessary, before publishing the final version of the list along with an overview of the comments received.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance